BACKGROUND: For the growing numbers of @entity28 elderly with @entity6 , the @entity5445 ( @entity8142 analogue (liraglutide) appears a safe way to promote and maintain substantial weight loss. Given this background, the aim of this study was to assess the effect of the liraglutide treatment, at doses up to 3.0  mg per day, on the body composition, focusing on @entity6288 , in overweight and @entity28 elderly with @entity6 ( @entity6 ). METHODS: A perspective study was carried out in overweight and @entity28 @entity6 @entity1 with HbA1c equal to 7.0  % (53  mmol/mol) ~10.0  % (86), under 3-month treatment (at least) of maximal dose of @entity2449 at stable regime, and additional liraglutide at doses up to 3.0  mg per day. Body composition markers such as skeletal muscle index (SMI), android and gynoid fat mass, and arms and legs fat free mass, was measured by dual-energy X-ray densitometry (DXA) at baseline and after 24 weeks of liraglutide treatment. @entity413 control was also carried out by @entity413 and HbA1c. RESULTS: Nine subjects (male/female 6/3, mean age 68.22      3.86  years, BMI 32.34      4.89  kg/m(2)) were evaluated. We noted a median decrease in BMI (-0.78  kg/m(2)), weight (-2000  g), fat mass (-1498  g) and android fat (-0.9  %), and a increase in SMI (+0.03  kg/m(2)) from baseline. Glycemic control also improved, with a median change @entity4051 c of -0.80  %. CONCLUSIONS: Twenty-four weeks of liraglutide treatment was associated with reductions in fat mass and android fat. In addition, in order to prevent @entity6288 , it preserved the muscular tropism.

Liraglutide and @entity28 in elderly: efficacy in fat loss and safety in order to prevent XXXX . A perspective case series study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4051 :: ('3039', 'Gene') :: ['HbA1'] @entity6 :: ('MESH:D003920', 'Disease') :: ['type 2 diabetes mellitus', 'diabetes', 'T2DM'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obese'] @entity6288 :: ('MESH:D055948', 'Disease') :: ['sarcopenia'] @entity8142 :: ('2740', 'Gene') :: ['GLP-1) receptor'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose', 'Glucose'] @entity5445 :: ('2641', 'Gene') :: ['glucagon-like peptide-1'] @entity2449 :: ('MESH:D008687', 'Chemical') :: ['metformin']
@entity6288 :: (MESH:D055948,Disease) :: ['sarcopenia']
